Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?

Immix Biopharma has a consensus price target implying 120.6% upside, signaling bullish analyst expectations for the stock. The article also notes an upward trend in earnings estimate revisions, which can support near-term share performance. The piece is speculative and valuation-driven rather than based on new operational results.

Analysis

Immix Biopharma has a consensus price target implying 120.6% upside, signaling bullish analyst expectations for the stock. The article also notes an upward trend in earnings estimate revisions, which can support near-term share performance. The piece is speculative and valuation-driven rather than based on new operational results.